PL3956310T3 - <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div> - Google Patents

<div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div>

Info

Publication number
PL3956310T3
PL3956310T3 PL20734624.8T PL20734624T PL3956310T3 PL 3956310 T3 PL3956310 T3 PL 3956310T3 PL 20734624 T PL20734624 T PL 20734624T PL 3956310 T3 PL3956310 T3 PL 3956310T3
Authority
PL
Poland
Prior art keywords
div
treatment
amino acid
acid derivatives
modified amino
Prior art date
Application number
PL20734624.8T
Other languages
English (en)
Inventor
Krzysztof KAMIŃSKI
Michał ABRAM
Marcin JAKUBIEC
Anna RAPACZ
Szczepan MOGILSKI
Gniewomir LATACZ
Marta STRUGA
Original Assignee
Uniwersytet Jagielloński
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński, Warszawski Uniwersytet Medyczny filed Critical Uniwersytet Jagielloński
Publication of PL3956310T3 publication Critical patent/PL3956310T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4042,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL20734624.8T 2019-04-16 2020-04-16 <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div> PL3956310T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL429656A PL240297B1 (pl) 2019-04-16 2019-04-16 Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
PCT/PL2020/050028 WO2020214043A1 (en) 2019-04-16 2020-04-16 Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders

Publications (1)

Publication Number Publication Date
PL3956310T3 true PL3956310T3 (pl) 2026-02-16

Family

ID=71138777

Family Applications (2)

Application Number Title Priority Date Filing Date
PL429656A PL240297B1 (pl) 2019-04-16 2019-04-16 Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
PL20734624.8T PL3956310T3 (pl) 2019-04-16 2020-04-16 <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div>

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL429656A PL240297B1 (pl) 2019-04-16 2019-04-16 Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Country Status (9)

Country Link
US (3) US12421189B2 (pl)
EP (2) EP3956310B1 (pl)
CN (1) CN113767088A (pl)
DK (1) DK3956310T3 (pl)
ES (1) ES3051032T3 (pl)
FI (1) FI3956310T3 (pl)
HU (1) HUE073599T2 (pl)
PL (2) PL240297B1 (pl)
WO (1) WO2020214043A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
PL243119B1 (pl) 2020-04-16 2023-06-26 Univ Jagiellonski Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
PL244897B1 (pl) * 2021-11-24 2024-03-25 Univ Jagiellonski Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych
CN116735761A (zh) * 2023-08-16 2023-09-12 四川省药品检验研究院(四川省医疗器械检测中心) 一种人血浆中布立西坦的uplc-ms/ms检测方法
WO2025085878A1 (en) * 2023-10-20 2025-04-24 Altay Therapeutics, Inc. N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
PL243119B1 (pl) 2020-04-16 2023-06-26 Univ Jagiellonski Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych

Also Published As

Publication number Publication date
US20250026717A1 (en) 2025-01-23
WO2020214043A1 (en) 2020-10-22
ES3051032T3 (en) 2025-12-23
EP4623910A3 (en) 2025-12-10
PL240297B1 (pl) 2022-03-14
US20250382265A1 (en) 2025-12-18
DK3956310T3 (da) 2025-10-27
US12331019B2 (en) 2025-06-17
PL429656A1 (pl) 2020-10-19
US12421189B2 (en) 2025-09-23
CN113767088A (zh) 2021-12-07
EP3956310B1 (en) 2025-08-06
FI3956310T3 (fi) 2025-11-13
EP4623910A2 (en) 2025-10-01
EP3956310A1 (en) 2022-02-23
HUE073599T2 (hu) 2026-01-28
US20220153694A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
PL3956310T3 (pl) &lt;div&gt;MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH&lt;/div&gt;
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
EP4640277A3 (en) C21-N-PYRAZOLYL STEROID WITH C3,3-19-NOR DISUBSTITUTION FOR THERAPEUTIC USE
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
SMT202400486T1 (it) Proteine di capside avv modificate per il trattamento della malattia artritica
EP4380588A4 (en) PSYCHOACTIVE DRUGS AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS AND PSYCHIATRIC AND NEUROLOGICAL DISORDERS
EP4359405A4 (en) BETA-LACTAM DERIVATIVES FOR TREATING DISEASES
IL287748A (en) Treatment and detection of inherited neuropathies and associated disorders
EP3581175A4 (en) PREPARATION FOR THE ADMINISTRATION OF A DRUG FOR THE TREATMENT OF MENTAL ILLNESSES OR CENTRAL NERVOUS SYSTEM DISORDERS
EP3649256A4 (en) METHOD OF TREATMENT INFLAMMATION AND RELATED DISEASES AND DISEASES BY INHIBITION OF ALPHA-PROTEIN KINASE 1
EP3927428C0 (en) NORKETOTIFEN FOR THE TREATMENT OF RESPIRATORY DISORDERS
DOP2022000093A (es) Inhibidores de adrenoreceptor adrac2
IL310870A (en) Quinazoline compounds for treatment of disease
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EP4058017A4 (en) DRUG FORMULATIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS
EP3488850A4 (en) NEW APPLICATION OF GZD824 IN THE TREATMENT OF LYMPHOBLASTIC LEUKEMIA.
EP4410296A4 (en) DIRECT TRANSDIFFERENTIATION FOR THE TREATMENT OF NEUROLOGICAL DISEASES
KR20240099184A9 (ko) 재생불량성 질환 치료를 위한 mrna 레귤론 요법
IL285160A (en) Low dose pridopidine for parkinson’s disease and other diseases associated with parkinsonism
EP3672593C0 (en) DRUGS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO VASOCONSTRICTION